Jubilant Pharmova Past Earnings Performance
Past criteria checks 1/6
Jubilant Pharmova's earnings have been declining at an average annual rate of -34.2%, while the Pharmaceuticals industry saw earnings growing at 15.5% annually. Revenues have been declining at an average rate of 7.7% per year. Jubilant Pharmova's return on equity is 10.1%, and it has net margins of 8.1%.
Key information
-34.2%
Earnings growth rate
-34.3%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | -7.7% |
Return on equity | 10.1% |
Net Margin | 8.1% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Jul 13Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Mar 14Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth
Dec 23These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Dec 02These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Jul 26Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
May 11Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Dec 10Jubilant Pharmova (NSE:JUBLPHARMA) Has Announced A Dividend Of ₹5.00
Aug 01Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?
Jun 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Mar 22Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Feb 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Dec 20Here's Why It's Unlikely That Jubilant Pharmova Limited's (NSE:JUBLPHARMA) CEO Will See A Pay Rise This Year
Sep 15Here's Why Jubilant Pharmova (NSE:JUBLPHARMA) Can Manage Its Debt Responsibly
Aug 21Time To Worry? Analysts Are Downgrading Their Jubilant Pharmova Limited (NSE:JUBLPHARMA) Outlook
Jun 08An Intrinsic Calculation For Jubilant Pharmova Limited (NSE:JUBLPHARMA) Suggests It's 39% Undervalued
May 25Analysts Just Made A Major Revision To Their Jubilant Pharmova Limited (NSE:JUBILANT) Revenue Forecasts
Feb 10Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBILANT)
Feb 08Shareholders Are Thrilled That The Jubilant Life Sciences (NSE:JUBILANT) Share Price Increased 217%
Jan 11Does Jubilant Life Sciences' (NSE:JUBILANT) CEO Salary Compare Well With Industry Peers?
Dec 31Read This Before Selling Jubilant Life Sciences Limited (NSE:JUBILANT) Shares
Dec 20Has Jubilant Life Sciences Limited's (NSE:JUBILANT) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Dec 08We Think Jubilant Life Sciences (NSE:JUBILANT) Can Stay On Top Of Its Debt
Nov 27What Kind Of Investors Own Most Of Jubilant Life Sciences Limited (NSE:JUBILANT)?
Nov 17Jubilant Life Sciences Limited Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next
Nov 06If You Like EPS Growth Then Check Out Jubilant Life Sciences (NSE:JUBILANT) Before It's Too Late
Oct 27Estimating The Fair Value Of Jubilant Life Sciences Limited (NSE:JUBILANT)
Oct 15Does Jubilant Life Sciences' (NSE:JUBILANT) Share Price Gain of 96% Match Its Business Performance?
Oct 03Trade Alert: The Independent Non-Executive Director Of Jubilant Life Sciences Limited (NSE:JUBILANT), Arun Seth, Has Just Spent ₹1.1m Buying 233% More Shares
Sep 21Revenue & Expenses Breakdown
How Jubilant Pharmova makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 68,477 | 5,528 | 22,212 | 0 |
31 Mar 24 | 67,029 | 771 | 22,160 | 0 |
31 Dec 23 | 66,223 | 378 | 22,444 | 0 |
30 Sep 23 | 64,977 | -446 | 22,308 | 0 |
30 Jun 23 | 64,169 | -1,017 | 21,845 | 0 |
31 Mar 23 | 62,817 | -610 | 22,151 | 0 |
31 Dec 22 | 61,313 | 964 | 21,726 | 0 |
30 Sep 22 | 58,893 | 1,631 | 21,292 | 0 |
30 Jun 22 | 59,472 | 3,004 | 20,734 | 0 |
31 Mar 22 | 61,302 | 4,139 | 20,739 | 0 |
31 Dec 21 | 61,824 | 5,273 | 20,300 | 0 |
30 Sep 21 | 66,432 | 6,953 | 19,875 | 0 |
30 Jun 21 | 65,771 | 6,993 | 19,448 | 0 |
31 Mar 21 | 60,985 | 5,741 | 19,440 | 0 |
31 Dec 20 | 92,659 | 8,339 | 22,683 | 0 |
30 Sep 20 | 89,744 | 7,759 | 22,527 | 0 |
30 Jun 20 | 88,655 | 8,013 | 22,166 | 0 |
31 Mar 20 | 59,758 | 6,778 | 18,843 | 0 |
31 Dec 19 | 91,486 | 5,385 | 21,451 | 0 |
30 Sep 19 | 92,105 | 5,959 | 21,061 | 0 |
30 Jun 19 | 92,140 | 5,569 | 19,785 | 0 |
31 Mar 19 | 91,108 | 5,745 | 20,093 | 0 |
31 Dec 18 | 89,772 | 8,286 | 19,458 | 0 |
30 Sep 18 | 86,679 | 7,803 | 18,691 | 0 |
30 Jun 18 | 80,402 | 6,982 | 16,971 | 0 |
31 Mar 18 | 75,178 | 6,428 | 16,187 | 0 |
31 Dec 17 | 68,641 | 6,381 | 14,748 | 0 |
30 Sep 17 | 62,545 | 5,449 | 13,610 | 0 |
30 Jun 17 | 59,982 | 5,613 | 12,454 | 0 |
31 Mar 17 | 58,614 | 5,757 | 12,792 | 0 |
31 Dec 16 | 58,013 | 4,763 | 12,382 | 0 |
30 Sep 16 | 57,097 | 4,795 | 12,107 | 0 |
30 Jun 16 | 57,762 | 4,612 | 11,929 | 0 |
31 Mar 16 | 57,491 | 3,918 | 11,674 | 0 |
31 Dec 15 | 58,376 | 4,035 | 16,033 | 0 |
30 Sep 15 | 59,036 | 2,754 | 15,918 | 0 |
30 Jun 15 | 58,117 | 655 | 15,779 | 0 |
31 Mar 15 | 58,262 | -578 | 11,284 | 0 |
31 Dec 14 | 58,863 | -17 | 14,543 | 0 |
30 Sep 14 | 58,837 | 1,529 | 14,636 | 0 |
30 Jun 14 | 58,641 | 1,664 | 11,213 | 0 |
31 Mar 14 | 58,034 | 1,090 | 14,957 | 0 |
31 Dec 13 | 55,983 | -207 | 13,800 | 0 |
30 Sep 13 | 54,658 | -1,375 | 13,373 | 0 |
Quality Earnings: JUBLPHARMA has a large one-off gain of ₹2.3B impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: JUBLPHARMA became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: JUBLPHARMA's earnings have declined by 34.2% per year over the past 5 years.
Accelerating Growth: JUBLPHARMA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: JUBLPHARMA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17%).
Return on Equity
High ROE: JUBLPHARMA's Return on Equity (10.1%) is considered low.